Free Trial
→ Washington Is Broke—and Eyeing Your Savings Next (From Priority Gold) (Ad) Buy PTGX Stock  Free PTGX Stock Alerts

Protagonist Therapeutics (PTGX) Financials

Protagonist Therapeutics logo
$45.82 -0.79 (-1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$44.30 -1.52 (-3.32%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Protagonist Therapeutics

Annual Income Statements for Protagonist Therapeutics

This table shows Protagonist Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 275 -79 -127 -126 -66 -77 -39 -37 -38 -15
Consolidated Net Income / (Loss)		 275 -79 -127 -126 -66 -77 -39 -37 -37 -15
Net Income / (Loss) Continuing Operations		 275 -79 -127 -126 -66 -77 -39 -37 -37 -15
Total Pre-Tax Income 		279 -79 -127 -126 -65 -78 -40 -37 -37 -15
Total Operating Income		 253 -94 -131 -126 -65 -81 -42 -38 -33 -15
Total Gross Profit		 434 60 27 27 29 0.23 31 20 0.00 0.00
Total Revenue		 434 60 27 27 29 0.23 31 20 0.00 0.00
Operating Revenue		 434 60 27 27 29 0.23 31 20 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 182 154 158 153 93 81 73 58 33 15
Selling, General & Admin Expense		 43 33 32 27 19 16 14 12 6.96 2.96
Research & Development Expense		 138 120 126 126 75 65 59 46 26 12
Total Other Income / (Expense), net		 27 15 3.98 0.29 -0.33 2.64 2.55 0.94 -4.48 -0.06
Interest & Investment Income		 26 15 4.06 0.44 0.90 2.81 2.57 0.95 0.24 0.02
Other Income / (Expense), net		 0.25 -0.20 -0.08 -0.15 -0.05 -0.00 -0.02 -0.01 -4.72 -0.08
Income Tax Expense		 4.22 0.00 0.00 - 1.31 -0.69 -0.80 - 0.00 -
Basic Earnings per Share		 $4.47 ($1.39) ($2.60) ($2.71) ($1.92) ($2.98) ($1.74) ($2.09) ($5.80) ($59.32)
Weighted Average Basic Shares Outstanding		 61.57M 56.76M 49.04M 46.32M 34.40M 25.89M 22.36M 17.69M 6.50M 251.72K
Diluted Earnings per Share		 $4.23 ($1.39) ($2.60) ($2.71) ($1.92) ($2.98) ($1.74) ($2.09) ($5.80) ($59.32)
Weighted Average Diluted Shares Outstanding		 65.08M 56.76M 49.04M 46.32M 34.40M 25.89M 22.36M 17.69M 6.50M 251.72K
Weighted Average Basic & Diluted Shares Outstanding		 61.38M 58.27M 51.28M 46.32M 34.40M 25.89M 22.36M 17.69M 6.50M 251.72K

Quarterly Income Statements for Protagonist Therapeutics

This table shows Protagonist Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -12 132 -33 -31 207 27 -34 -38 -34 -34 -31
Consolidated Net Income / (Loss)		 -12 132 -33 -31 207 27 -34 -38 -34 -34 -31
Net Income / (Loss) Continuing Operations		 -12 132 -33 -31 207 27 -34 -38 -34 -34 -31
Total Pre-Tax Income 		-12 134 -34 -31 211 27 -34 -38 -34 -106 0.00
Total Operating Income		 -19 127 -41 -39 206 23 -38 -42 -36 -37 -32
Total Gross Profit		 28 171 4.68 4.17 255 60 0.00 0.00 0.00 - 0.00
Total Revenue		 28 171 4.68 4.17 255 60 0.00 0.00 0.00 - 0.00
Operating Revenue		 28 171 4.68 4.17 255 60 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 48 44 46 43 49 37 38 42 36 37 32
Selling, General & Admin Expense		 12 8.95 10 9.44 15 8.05 7.66 9.17 8.61 6.63 6.90
Research & Development Expense		 36 35 36 34 34 29 31 33 27 30 25
Total Other Income / (Expense), net		 7.66 6.88 7.82 7.50 4.36 4.29 4.22 3.89 2.30 2.32 1.07
Interest & Investment Income		 7.57 6.85 7.68 7.40 4.38 4.24 4.25 3.91 2.49 2.25 1.16
Other Income / (Expense), net		 0.08 0.03 0.14 0.10 -0.02 0.04 -0.03 -0.02 -0.20 0.07 -0.09
Income Tax Expense		 0.00 1.99 -0.42 -0.68 3.33 - 0.00 0.00 0.00 - -
Basic Earnings per Share		 ($0.19) $2.10 ($0.54) ($0.50) $3.41 $0.54 ($0.58) ($0.68) ($0.67) ($0.69) ($0.64)
Weighted Average Basic Shares Outstanding		 62.96M 61.57M 61.77M 61.31M 60.86M 56.76M 59.18M 56.78M 50.57M 49.04M 49.11M
Diluted Earnings per Share		 ($0.19) $2.01 ($0.54) ($0.50) $3.26 $0.54 ($0.58) ($0.68) ($0.67) ($0.69) ($0.64)
Weighted Average Diluted Shares Outstanding		 62.96M 65.08M 61.77M 61.31M 63.60M 56.76M 59.18M 56.78M 50.57M 49.04M 49.11M
Weighted Average Basic & Diluted Shares Outstanding		 61.98M 61.38M 59.60M 58.90M 58.65M 58.27M 57.68M 57.53M 57.25M 51.28M 49.20M

Annual Cash Flow Statements for Protagonist Therapeutics

This table details how cash moves in and out of Protagonist Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -89 61 2.08 6.07 84 -49 -24 85 17 -5.23
Net Cash From Operating Activities		 184 -70 -108 -108 -72 -42 -50 3.87 -30 -14
Net Cash From Continuing Operating Activities		 184 -70 -108 -108 -72 -42 -50 3.87 -30 -14
Net Income / (Loss) Continuing Operations		 275 -79 -127 -126 -66 -77 -39 -37 -37 -15
Consolidated Net Income / (Loss)		 275 -79 -127 -126 -66 -77 -39 -37 -37 -15
Depreciation Expense		 0.83 0.98 1.03 0.81 0.95 0.73 0.53 0.41 0.32 0.25
Amortization Expense		 -6.81 -2.23 1.79 3.79 1.81 1.20 0.21 0.69 0.12 -0.01
Non-Cash Adjustments To Reconcile Net Income		 38 29 24 16 9.92 5.70 6.26 4.18 6.88 0.18
Changes in Operating Assets and Liabilities, net		 -123 -19 -7.77 -3.31 -19 28 -18 36 -0.11 0.05
Net Cash From Investing Activities		 -299 -39 91 -16 -91 -54 2.21 16 -59 -8.26
Net Cash From Continuing Investing Activities		 -299 -39 91 -16 -91 -54 2.21 16 -59 -8.26
Purchase of Property, Plant & Equipment		 -1.36 -0.61 -0.80 -1.10 -0.47 -0.97 -0.49 -0.67 -0.35 -0.40
Purchase of Investments		 -622 -191 -215 -287 -280 -167 -71 -40 -73 -7.87
Sale and/or Maturity of Investments		 324 152 307 272 190 114 74 56 14 0.00
Net Cash From Financing Activities		 26 170 19 130 248 46 24 66 106 17
Net Cash From Continuing Financing Activities		 26 170 19 130 248 46 24 66 106 17
Issuance of Debt		 0.00 24 15 0.00 42 44 1.51 - - -
Issuance of Common Equity		 26 113 4.47 130 216 1.78 23 66 84 0.06
Other Financing Activities, net		 -0.60 34 -0.19 -0.19 - 0.00 - - - -
Effect of Exchange Rate Changes		 0.00 0.00 -0.09 -0.13 0.18 - - - - -
Cash Income Taxes Paid		 1.53 0.00 0.00 - - - - - - -

Quarterly Cash Flow Statements for Protagonist Therapeutics

This table details how cash moves in and out of Protagonist Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 42 -34 -225 183 -14 -44 -4.86 108 1.94 -27 33
Net Cash From Operating Activities		 125 -29 -28 269 -27 17 -27 -26 -34 -32 -25
Net Cash From Continuing Operating Activities		 125 -29 -28 269 -27 17 -27 -26 -34 -32 -25
Net Income / (Loss) Continuing Operations		 -12 132 -33 -31 207 27 -34 -38 -34 -34 -31
Consolidated Net Income / (Loss)		 -12 132 -33 -31 207 27 -34 -38 -34 -34 -31
Depreciation Expense		 0.24 0.12 0.23 0.24 0.24 0.25 0.24 0.24 0.25 0.26 0.27
Amortization Expense		 -2.29 -2.34 -2.42 -1.01 -1.03 -0.76 -0.42 -0.38 -0.67 -0.33 0.49
Non-Cash Adjustments To Reconcile Net Income		 157 9.09 10 8.94 9.35 6.60 6.77 8.34 7.58 5.51 5.95
Changes in Operating Assets and Liabilities, net		 -17 -168 -2.63 291 -243 -16 0.91 4.02 -7.78 -2.88 -0.68
Net Cash From Investing Activities		 -94 -8.73 -209 -88 6.07 -61 -14 26 9.83 3.94 57
Net Cash From Continuing Investing Activities		 -94 -8.73 -209 -88 6.07 -61 -14 26 9.83 3.94 57
Purchase of Property, Plant & Equipment		 -0.55 -0.31 -0.78 -0.03 -0.24 -0.02 -0.40 -0.18 -0.01 -0.07 -0.16
Purchase of Investments		 -214 -114 -267 -175 -66 -98 -59 -6.06 -28 -81 -32
Sale and/or Maturity of Investments		 120 106 59 87 72 37 46 32 38 85 90
Net Cash From Financing Activities		 11 4.03 12 2.57 7.20 0.53 35 108 26 0.55 0.68
Net Cash From Continuing Financing Activities		 11 4.03 12 2.57 7.20 0.53 35 108 26 0.55 0.68
Issuance of Common Equity		 12 4.03 12 2.57 7.80 0.53 0.94 109 2.26 0.55 0.68
Other Financing Activities, net		 -0.48 - - - -0.60 - 34 -0.67 -0.10 - -0.00

Annual Balance Sheets for Protagonist Therapeutics

This table presents Protagonist Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 745 358 248 348 324 155 139 164 94 15
Total Current Assets		 592 356 243 341 316 145 138 151 83 0.00
Cash & Equivalents		 97 187 126 124 117 33 82 106 21 4.06
Short-Term Investments		 322 155 112 203 188 100 47 38 57 7.87
Prepaid Expenses		 7.73 3.96 5.71 9.48 6.28 5.53 2.62 3.77 3.39 1.56
Other Current Assets		 165 10 0.01 - - - - - - 0.72
Plant, Property, & Equipment, net		 3.19 1.20 1.57 1.80 1.46 1.68 0.86 0.88 0.56 0.61
Total Noncurrent Assets		 150 1.18 3.29 5.16 7.40 7.93 1.11 12 10 0.03
Long-Term Investments		 140 0.00 - - 2.00 0.00 - 11 10 0.00
Other Noncurrent Operating Assets		 9.64 1.18 3.29 5.16 5.40 6.49 0.45 0.45 0.03 0.03
Total Liabilities & Shareholders' Equity		 745 358 248 348 324 155 139 164 94 15
Total Liabilities		 69 21 32 48 45 75 27 43 6.44 5.25
Total Current Liabilities		 47 21 31 44 40 35 26 43 6.44 3.13
Accounts Payable		 25 20 29 40 24 16 18 11 6.44 3.13
Current Deferred Revenue		 19 0.00 0.07 1.60 14 18 8.22 32 - -
Current Deferred & Payable Income Tax Liabilities		 2.69 0.00 - - - - - - - -
Other Current Liabilities		 0.51 1.14 2.52 2.20 1.46 1.26 - - - -
Total Noncurrent Liabilities		 22 0.00 1.14 3.66 4.62 40 0.80 0.55 0.00 2.12
Noncurrent Deferred Revenue		 12 0.00 - - - 24 0.80 0.55 0.00 -
Other Noncurrent Operating Liabilities		 10 0.00 1.14 3.66 4.62 5.96 - - - 2.12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 675 337 216 300 280 80 113 121 88 -27
Total Preferred & Common Equity		 675 337 216 300 280 80 113 121 88 -27
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 675 337 216 300 280 80 113 121 88 -27
Common Stock		 1,016 952 753 710 563 298 253 222 152 0.12
Retained Earnings		 -341 -616 -537 -409 -284 -218 -140 -102 -65 -27
Accumulated Other Comprehensive Income / (Loss)		 -0.08 -0.11 -0.36 -0.30 0.03 -0.22 -0.23 -0.01 -0.25 -0.10

Quarterly Balance Sheets for Protagonist Therapeutics

This table presents Protagonist Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 742 604 615 629 330 320 240 282
Total Current Assets		 606 477 571 628 325 317 236 277
Cash & Equivalents		 140 131 356 173 231 235 128 153
Short-Term Investments		 435 338 208 150 90 78 103 115
Note & Lease Receivable		 0.00 - - - - - - -
Prepaid Expenses		 8.68 8.05 6.89 4.88 4.13 3.50 4.93 9.06
Other Current Assets		 23 0.00 0.04 300 0.00 - - -
Plant, Property, & Equipment, net		 3.53 2.47 1.78 1.11 1.42 1.26 1.34 1.78
Total Noncurrent Assets		 133 125 42 0.61 3.71 2.26 2.78 3.77
Long-Term Investments		 124 115 31 - 1.99 - - -
Other Noncurrent Operating Assets		 9.23 10 10 0.61 1.73 2.26 2.78 3.77
Total Liabilities & Shareholders' Equity		 742 604 615 629 330 320 240 282
Total Liabilities		 53 72 73 69 28 26 24 39
Total Current Liabilities		 35 45 42 40 28 26 23 37
Accounts Payable		 15 24 19 20 26 24 21 34
Current Deferred Revenue		 17 20 20 16 0.00 0.00 0.00 0.00
Current Deferred & Payable Income Tax Liabilities		 1.89 1.05 2.65 3.33 - - - -
Other Current Liabilities		 1.57 0.05 0.00 0.47 1.80 2.45 2.60 2.43
Total Noncurrent Liabilities		 18 27 32 29 0.00 0.00 0.46 1.80
Noncurrent Deferred Revenue		 8.18 17 21 29 - - - -
Other Noncurrent Operating Liabilities		 9.79 11 11 - 0.00 0.00 0.46 1.80
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 689 532 541 560 302 294 216 244
Total Preferred & Common Equity		 689 532 541 560 302 294 216 244
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 689 532 541 560 302 294 216 244
Common Stock		 1,041 1,003 981 969 945 903 787 747
Retained Earnings		 -352 -472 -439 -408 -643 -609 -570 -503
Accumulated Other Comprehensive Income / (Loss)		 0.09 1.34 -0.25 -0.23 -0.17 -0.20 -0.12 -0.48

Annual Metrics And Ratios for Protagonist Therapeutics

This table displays calculated financial ratios and metrics derived from Protagonist Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 624.06% 125.73% -2.84% -4.44% 12,293.07% -99.25% 54.14% 0.00% 0.00% 0.00%
EBITDA Growth		 359.82% 26.06% -5.97% -96.42% 21.36% -89.12% -12.89% 0.38% -152.43% -35.16%
EBIT Growth		 369.67% 28.60% -4.33% -95.15% 19.82% -90.41% -11.57% -1.39% -151.29% -34.17%
NOPAT Growth		 479.86% 28.71% -4.39% -95.06% 19.88% -90.50% -11.54% -16.01% -120.81% -58.75%
Net Income Growth		 448.54% 38.02% -1.47% -89.80% 14.30% -98.30% -5.32% 0.59% -150.22% -34.19%
EPS Growth		 404.32% 46.54% 4.06% -41.15% 35.57% -71.26% 16.75% 63.97% 90.22% -20.13%
Operating Cash Flow Growth		 362.19% 35.05% -0.25% -48.81% -74.55% 16.86% -1,389.95% 112.92% -108.36% -85.78%
Free Cash Flow Firm Growth		 255.35% 15.17% -8.57% -48.50% -104.52% 38.76% -693.17% 132.42% -211.76% 0.00%
Invested Capital Growth		 2,450.81% 77.28% 19.09% 4.73% 34.80% -164.67% 53.07% -16,976.96% 91.27% 0.00%
Revenue Q/Q Growth		 34.17% 0.00% -24.48% 12.16% 11.41% 271.11% -22.40% 128.48% 0.00% 0.00%
EBITDA Q/Q Growth		 70.30% 38.32% -1.69% -15.73% -1.99% -1.87% -41.54% 17.99% 0.00% 0.00%
EBIT Q/Q Growth		 69.43% 38.81% 0.44% -16.87% -2.68% -2.40% -39.25% 17.20% 0.00% 0.00%
NOPAT Q/Q Growth		 67.00% 38.88% 0.38% -16.89% -2.43% -2.40% -39.18% 17.22% 0.00% 0.00%
Net Income Q/Q Growth		 61.07% 43.80% 2.09% -16.76% -2.14% -4.94% -38.47% 18.15% 0.00% 0.00%
EPS Q/Q Growth		 53.26% 46.95% 3.35% -16.31% 9.86% -0.68% -42.62% -103.94% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -20.03% 40.89% -4.54% -8.09% -6.74% -11.12% 7.44% -53.58% -19.74% 0.00%
Free Cash Flow Firm Q/Q Growth		 -28.87% 25.45% -6.35% -7.78% -7.50% -7.98% 10.58% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 326.08% 76.00% 8.71% -17.84% 7.25% -2.18% -12.21% 26.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 56.88% -158.52% -483.93% -443.72% -215.88% -34,022.51% -134.38% -183.48% 0.00% 0.00%
Operating Margin		 58.20% -156.09% -494.24% -460.01% -225.36% -34,857.58% -136.68% -188.89% 0.00% 0.00%
EBIT Margin		 58.26% -156.42% -494.54% -460.55% -225.52% -34,858.01% -136.75% -188.93% 0.00% 0.00%
Profit (Net Income) Margin		 63.34% -131.59% -479.26% -458.94% -231.07% -33,414.29% -125.87% -184.20% 0.00% 0.00%
Tax Burden Percent		 98.49% 100.00% 100.00% 100.00% 102.01% 99.11% 97.99% 100.00% 100.00% 100.00%
Interest Burden Percent		 110.40% 84.13% 96.91% 99.65% 100.44% 96.72% 93.93% 97.50% 99.44% 99.87%
Effective Tax Rate		 1.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 447.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 442.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -393.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 54.39% -28.59% -49.41% -43.32% -36.79% -80.20% -33.39% -35.50% -76.53% -154.84%
Cash Return on Invested Capital (CROIC)		 110.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 45.91% -30.98% -44.14% -37.49% -26.94% -54.70% -27.89% -29.42% 0.00% 0.00%
Return on Assets (ROA)		 49.91% -26.06% -42.78% -37.36% -27.60% -52.44% -25.68% -28.68% 0.00% 0.00%
Return on Common Equity (ROCE)		 54.39% -28.59% -49.41% -43.32% -36.79% -80.20% -33.39% -35.50% -47.39% 442.11%
Return on Equity Simple (ROE_SIMPLE)		 40.75% -23.45% -59.09% -41.85% -23.66% -96.53% -34.59% -30.64% -42.46% 54.23%
Net Operating Profit after Tax (NOPAT)		 249 -66 -92 -88 -45 -56 -30 -27 -23 -10
NOPAT Margin		 57.32% -109.26% -345.97% -322.01% -157.75% -24,400.30% -95.68% -132.22% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 5.81% -4.63% -12.56% -11.80% -9.74% -16.52% -6.57% -8.58% -28.71% -75.46%
Return On Investment Capital (ROIC_SIMPLE)		 36.88% -19.47% -42.65% - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 10.00% 55.82% 119.40% 99.41% 65.10% 6,817.75% 44.29% 58.71% 0.00% 0.00%
R&D to Revenue		 31.80% 200.27% 474.83% 460.60% 260.26% 28,139.83% 192.39% 230.18% 0.00% 0.00%
Operating Expenses to Revenue		 41.80% 256.09% 594.24% 560.01% 325.36% 34,957.58% 236.68% 288.89% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 253 -94 -131 -126 -65 -81 -42 -38 -37 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 247 -95 -129 -121 -62 -79 -42 -37 -37 -15
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.41 3.93 2.49 5.44 2.76 2.40 1.45 3.53 4.20 0.00
Price to Tangible Book Value (P/TBV)		 3.41 3.93 2.49 5.44 2.76 2.40 1.45 3.53 4.20 0.00
Price to Revenue (P/Rev)		 5.30 22.04 20.19 59.67 26.94 830.33 5.26 21.23 0.00 0.00
Price to Earnings (P/E)		 8.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 11.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 14.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 4.01 16.35 11.26 47.72 16.19 296.85 1.10 13.48 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 7.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 6.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 6.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.46 0.00 0.00 0.00 0.00 0.00 0.00 69.86 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 13.61 0.00 0.00 0.00 0.00 0.00 0.00 33.38 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00
Financial Leverage		 -0.89 -1.05 -1.09 -1.10 -1.20 -1.31 -1.22 -1.17 -1.03 -1.24
Leverage Ratio		 1.09 1.10 1.16 1.16 1.33 1.53 1.30 1.24 1.12 1.55
Compound Leverage Factor		 1.20 0.92 1.12 1.16 1.34 1.48 1.22 1.21 1.11 1.55
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 10.91% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 10.91% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 385.54%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 89.09% 100.00% 100.00% 100.00% -285.54%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.12 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.57 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.12 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.17 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.19 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.17 0.00 0.00 0.00 0.00
Altman Z-Score		 21.82 35.32 6.32 18.80 9.54 -1.29 2.39 5.21 32.98 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 38.08% 385.54%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 12.48 16.71 7.80 7.74 7.84 4.10 5.26 3.55 12.94 0.00
Quick Ratio		 8.84 16.06 7.61 7.46 7.66 3.95 5.10 3.43 12.06 3.81
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 128 -82 -97 -89 -60 -29 -48 8.11 -25 -8.02
Operating Cash Flow to CapEx		 13,590.55% -11,533.00% -13,602.14% -9,797.00% -15,389.38% -4,294.42% -10,277.16% 581.38% -8,637.46% -3,605.26%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -50.90 -174.22 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -61.27 -245.72 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -61.67 -251.44 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.79 0.20 0.09 0.08 0.12 0.00 0.20 0.16 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 13.71 6.24 0.04 9.66 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 198.15 43.48 15.81 16.78 18.22 0.18 35.55 27.85 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 26.63 58.53 8,960.67 37.79 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 26.63 58.53 8,960.67 37.79 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 116 -4.94 -22 -27 -28 -43 -16 -35 -0.20 -2.34
Invested Capital Turnover		 7.81 -4.50 -1.09 -0.99 -0.80 -0.01 -1.21 -1.15 0.00 0.00
Increase / (Decrease) in Invested Capital		 121 17 5.13 1.33 15 -27 18 -35 2.13 -2.34
Enterprise Value (EV)		 1,741 981 299 1,305 463 69 34 271 280 0.00
Market Capitalization		 2,300 1,323 537 1,632 771 192 163 426 368 0.00
Book Value per Share		 $11.33 $5.84 $4.38 $6.29 $7.31 $2.94 $4.65 $5.89 $5.24 ($108.85)
Tangible Book Value per Share		 $11.33 $5.84 $4.38 $6.29 $7.31 $2.94 $4.65 $5.89 $5.24 ($108.85)
Total Capital		 675 337 216 300 280 90 113 121 88 9.60
Total Debt		 0.00 0.00 0.00 0.00 0.00 9.79 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 9.79 0.00 0.00 0.00 0.00
Net Debt		 -559 -342 -237 -327 -308 -123 -129 -155 -88 -12
Capital Expenditures (CapEx)		 1.36 0.61 0.80 1.10 0.47 0.97 0.49 0.67 0.35 0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 125 -7.31 -25 -30 -30 -23 -18 -36 -0.80 -15
Debt-free Net Working Capital (DFNWC)		 544 334 212 297 275 110 111 108 77 -3.13
Net Working Capital (NWC)		 544 334 212 297 275 110 111 108 77 -3.13
Net Nonoperating Expense (NNE)		 -26 13 35 37 21 21 9.34 10 14 4.50
Net Nonoperating Obligations (NNO)		 -559 -342 -237 -327 -308 -123 -129 -155 -88 -12
Total Depreciation and Amortization (D&A)		 -5.98 -1.26 2.82 4.61 2.76 1.93 0.73 1.09 0.43 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 28.85% -12.19% -95.77% -110.32% -106.38% -10,009.52% -56.65% -177.54% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 125.28% 557.17% 797.18% 1,084.62% 961.87% 47,577.92% 360.05% 540.26% 0.00% 0.00%
Net Working Capital to Revenue		 125.28% 557.17% 797.18% 1,084.62% 961.87% 47,577.92% 360.05% 540.26% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $4.47 ($1.39) ($2.60) ($2.71) ($1.92) ($2.98) ($1.74) ($2.09) ($5.80) ($59.32)
Adjusted Weighted Average Basic Shares Outstanding		 61.57M 56.76M 49.04M 48.41M 43.81M 27.29M 23.35M 21.10M 16.79M 251.72K
Adjusted Diluted Earnings per Share		 $4.23 ($1.39) ($2.60) ($2.71) ($1.92) ($2.98) ($1.74) ($2.09) ($5.80) ($59.32)
Adjusted Weighted Average Diluted Shares Outstanding		 65.08M 56.76M 49.04M 48.41M 43.81M 27.29M 23.35M 21.10M 16.79M 251.72K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.71) ($1.92) ($2.98) ($1.74) ($2.09) ($5.80) ($59.32)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.38M 58.27M 51.28M 46.32M 34.40M 25.89M 22.36M 17.69M 6.50M 251.72K
Normalized Net Operating Profit after Tax (NOPAT)		 249 -66 -92 -88 -45 -56 -30 -27 -23 -10
Normalized NOPAT Margin		 57.32% -109.26% -345.97% -322.01% -157.75% -24,400.30% -95.68% -132.22% 0.00% 0.00%
Pre Tax Income Margin		 64.32% -131.59% -479.26% -458.94% -226.51% -33,713.42% -128.45% -184.20% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -54.57 -476.46 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -38.18 -333.52 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -54.97 -482.18 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -38.57 -339.24 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Protagonist Therapeutics

This table displays calculated financial ratios and metrics derived from Protagonist Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -88.89% 184.40% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00% 0.00% -100.00%
EBITDA Growth		 -110.38% 451.83% -12.89% 7.17% 660.86% 161.82% -21.85% -4.76% -84.05% -6.22% 7.10%
EBIT Growth		 -109.32% 449.13% -7.70% 8.68% 669.61% 163.36% -18.43% -2.05% -71.66% 1.58% 4.53%
NOPAT Growth		 -106.66% 441.86% -8.16% 8.41% 905.29% 190.17% -18.65% -2.20% -70.63% 1.35% 4.78%
Net Income Growth		 -105.62% 381.70% 2.62% 20.40% 714.80% 179.94% -9.20% 6.28% -61.13% 7.35% 7.61%
EPS Growth		 -105.83% 272.22% 6.90% 26.47% 586.57% 178.26% 9.38% 19.05% -55.81% 11.54% 8.57%
Operating Cash Flow Growth		 557.05% -272.04% -4.70% 1,123.79% 20.14% 153.61% -5.60% -92.43% 8.81% -17.43% 11.48%
Free Cash Flow Firm Growth		 572.38% -38.76% 105.86% 122.30% -249.16% 120.34% -39.17% -22.01% 55.36% -12.66% 31.11%
Invested Capital Growth		 -103.71% 2,450.81% -149.51% -179.94% 1,729.72% 77.28% 13.58% 19.15% -315.61% 19.09% -4.43%
Revenue Q/Q Growth		 -83.40% 3,550.01% 12.19% -98.37% 324.92% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -117.08% 386.39% -10.23% -119.21% 810.20% 158.59% 9.35% -16.03% -0.33% -15.48% 22.07%
EBIT Q/Q Growth		 -115.16% 406.96% -6.76% -118.76% 793.30% 160.21% 9.48% -17.00% 0.63% -12.52% 21.99%
NOPAT Q/Q Growth		 -110.82% 530.41% -6.86% -113.37% 1,158.51% 185.91% 9.51% -17.58% 1.36% -13.04% 22.05%
Net Income Q/Q Growth		 -108.85% 496.49% -8.47% -114.77% 658.51% 180.15% 11.32% -14.04% 1.37% -9.48% 23.89%
EPS Q/Q Growth		 -109.45% 472.22% -8.00% -115.34% 503.70% 193.10% 14.71% -1.49% 2.90% -7.81% 23.81%
Operating Cash Flow Q/Q Growth		 529.65% -4.72% -110.37% 1,079.34% -261.73% 163.73% -1.42% 23.61% -8.57% -25.53% -84.83%
Free Cash Flow Firm Q/Q Growth		 5,998.56% 116.95% -76.91% 115.47% -7,235.99% 120.76% 12.17% -142.16% 53.95% -42.09% 23.00%
Invested Capital Q/Q Growth		 -107.60% 326.08% 5.09% -122.76% 4,913.95% 76.00% -6.49% -32.49% 32.90% 8.71% 0.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -75.13% 73.01% -930.55% -947.11% 80.60% 37.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -68.18% 74.30% -886.70% -930.96% 80.92% 38.42% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -67.89% 74.32% -883.68% -928.63% 80.91% 38.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -41.15% 77.17% -710.37% -734.73% 81.32% 45.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 98.51% 98.75% 97.84% 98.42% 100.00% 100.00% 100.00% 100.00% 32.12% 0.00%
Interest Burden Percent		 60.61% 105.40% 81.40% 80.87% 102.12% 118.37% 88.91% 90.77% 93.12% 292.12% 0.00%
Effective Tax Rate		 0.00% 1.49% 0.00% 0.00% 1.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -86.63% 571.94% 0.00% 0.00% 224.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -86.99% 570.43% 0.00% 0.00% 223.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 71.05% -507.75% 0.00% 0.00% -159.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -15.58% 64.18% 40.97% 40.69% 65.70% -28.59% -51.48% -48.97% -54.13% -49.41% -45.39%
Cash Return on Invested Capital (CROIC)		 0.00% 110.18% 0.00% 0.00% -43.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -20.57% 58.56% -612.78% -633.83% 58.64% 7.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -12.47% 60.80% -492.61% -501.48% 58.94% 9.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -15.58% 64.18% 40.97% 40.69% 65.70% -28.59% -51.48% -48.97% -54.13% -49.41% -45.39%
Return on Equity Simple (ROE_SIMPLE)		 8.16% 0.00% 32.12% 31.40% 28.93% 0.00% -46.49% -46.80% -64.85% 0.00% -53.41%
Net Operating Profit after Tax (NOPAT)		 -14 125 -29 -27 203 23 -27 -30 -25 -26 -23
NOPAT Margin		 -47.73% 73.19% -620.69% -651.67% 79.64% 38.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.36% 1.51% -0.93% -0.76% 1.55% 1.48% -2.47% -2.91% -3.18% -3.06% -2.78%
Return On Investment Capital (ROIC_SIMPLE)		 -1.96% 18.49% - - - 6.85% - - - -11.86% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 41.45% 5.25% 217.28% 226.54% 5.85% 13.42% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 126.74% 20.46% 769.41% 804.42% 13.23% 48.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 168.18% 25.70% 986.70% 1,030.96% 19.08% 61.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 127 -41 -39 206 23 -38 -42 -36 -36 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 125 -44 -39 205 23 -39 -43 -37 -37 -32
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.31 3.41 4.98 3.75 2.98 3.93 3.18 5.38 5.46 2.49 1.70
Price to Tangible Book Value (P/TBV)		 4.31 3.41 4.98 3.75 2.98 3.93 3.18 5.38 5.46 2.49 1.70
Price to Revenue (P/Rev)		 14.29 5.30 8.19 6.37 5.30 22.04 0.00 0.00 1,372.91 20.19 11.76
Price to Earnings (P/E)		 52.83 8.36 15.51 11.96 10.29 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.89% 11.96% 6.45% 8.36% 9.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 14.99 0.00 0.00 5.66 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.93 4.01 6.39 4.50 4.27 16.35 0.00 0.00 1,104.27 11.26 4.16
Enterprise Value to EBITDA (EV/EBITDA)		 108.52 7.05 14.25 9.57 9.15 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 82.35 6.88 13.84 9.43 9.05 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 84.73 6.99 13.86 9.44 9.05 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.74 9.46 8.98 6.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 8.30 13.61 11.49 7.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.82 -0.89 -1.09 -1.09 -0.71 -1.05 -1.08 -1.08 -1.04 -1.09 -1.08
Leverage Ratio		 1.10 1.09 1.12 1.12 1.12 1.10 1.12 1.12 1.14 1.16 1.14
Compound Leverage Factor		 0.67 1.15 0.91 0.91 1.14 1.30 1.00 1.02 1.06 3.37 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 34.01 21.26 22.18 16.98 16.34 36.39 18.63 33.93 27.11 7.58 4.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.26 12.48 10.70 13.73 15.72 16.71 11.66 12.01 10.15 7.80 7.53
Quick Ratio		 16.36 8.84 10.51 13.56 8.08 16.06 11.51 11.87 9.94 7.61 7.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 233 3.82 1.76 7.63 -49 6.24 -30 -34 -14 -31 -22
Operating Cash Flow to CapEx		 23,002.39% -9,412.26% -3,595.23% 959,364.29% -11,334.30% 89,263.16% -6,586.88% -14,907.95% -343,470.00% -45,192.86% -15,556.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.30 0.79 0.69 0.68 0.72 0.20 0.00 0.00 0.00 0.09 0.11
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 25.48
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 89.55 198.15 166.52 209.74 256.89 43.48 0.00 0.00 0.50 15.81 20.08
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5,354.11 0.00 14.33
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5,354.11 0.00 14.33
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.83 116 -51 -54 238 -4.94 -21 -19 -15 -22 -24
Invested Capital Turnover		 1.82 7.81 -9.00 -8.69 2.82 -4.50 0.00 0.00 -0.09 -1.09 -1.51
Increase / (Decrease) in Invested Capital		 -247 121 -31 -35 252 17 3.23 4.58 -11 5.13 -1.01
Enterprise Value (EV)		 2,271 1,741 2,067 1,437 1,346 981 637 1,268 949 299 146
Market Capitalization		 2,969 2,300 2,651 2,032 1,669 1,323 960 1,581 1,179 537 414
Book Value per Share		 $11.23 $11.33 $9.03 $9.23 $9.21 $5.84 $5.25 $5.14 $4.22 $4.38 $4.96
Tangible Book Value per Share		 $11.23 $11.33 $9.03 $9.23 $9.21 $5.84 $5.25 $5.14 $4.22 $4.38 $4.96
Total Capital		 689 675 532 541 560 337 302 294 216 216 244
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -698 -559 -583 -595 -323 -342 -323 -313 -231 -237 -267
Capital Expenditures (CapEx)		 0.55 0.31 0.78 0.03 0.24 0.02 0.40 0.18 0.01 0.07 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.61 125 -37 -35 265 -7.31 -24 -23 -18 -25 -28
Debt-free Net Working Capital (DFNWC)		 571 544 432 529 588 334 297 291 213 212 240
Net Working Capital (NWC)		 571 544 432 529 588 334 297 291 213 212 240
Net Nonoperating Expense (NNE)		 -1.86 -6.78 4.19 3.46 -4.29 -4.29 7.28 8.81 8.51 8.63 8.62
Net Nonoperating Obligations (NNO)		 -698 -559 -583 -595 -323 -342 -323 -313 -231 -237 -267
Total Depreciation and Amortization (D&A)		 -2.05 -2.22 -2.19 -0.77 -0.80 -0.52 -0.18 -0.14 -0.42 -0.07 0.76
Debt-free, Cash-free Net Working Capital to Revenue		 -1.74% 28.85% -11.28% -10.86% 84.14% -12.19% 0.00% 0.00% -2,124.80% -95.77% -78.34%
Debt-free Net Working Capital to Revenue		 274.66% 125.28% 133.48% 165.88% 186.58% 557.17% 0.00% 0.00% 24,738.88% 797.18% 681.47%
Net Working Capital to Revenue		 274.66% 125.28% 133.48% 165.88% 186.58% 557.17% 0.00% 0.00% 24,738.88% 797.18% 681.47%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.19) $2.10 ($0.54) ($0.50) $3.41 $0.54 ($0.58) ($0.68) ($0.67) ($0.69) ($0.64)
Adjusted Weighted Average Basic Shares Outstanding		 62.96M 61.57M 61.77M 61.31M 60.86M 56.76M 59.18M 56.78M 50.57M 49.04M 49.11M
Adjusted Diluted Earnings per Share		 ($0.19) $2.01 ($0.54) ($0.50) $3.26 $0.54 ($0.58) ($0.68) ($0.67) ($0.69) ($0.64)
Adjusted Weighted Average Diluted Shares Outstanding		 62.96M 65.08M 61.77M 61.31M 63.60M 56.76M 59.18M 56.78M 50.57M 49.04M 49.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.98M 61.38M 59.60M 58.90M 58.65M 58.27M 57.68M 57.53M 57.25M 51.28M 49.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 125 -29 -27 203 16 -27 -30 -25 -26 -23
Normalized NOPAT Margin		 -47.73% 73.19% -620.69% -651.67% 79.64% 26.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -41.15% 78.33% -719.36% -750.95% 82.63% 45.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Protagonist Therapeutics' Financials

When does Protagonist Therapeutics's financial year end?

According to the most recent income statement we have on file, Protagonist Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Protagonist Therapeutics' net income changed over the last 9 years?

Protagonist Therapeutics' net income appears to be on a downward trend, with a most recent value of $275.19 million in 2024, falling from -$14.86 million in 2015. The previous period was -$78.96 million in 2023. Check out Protagonist Therapeutics' forecast to explore projected trends and price targets.

What is Protagonist Therapeutics's operating income?
Protagonist Therapeutics's total operating income in 2024 was $252.84 million, based on the following breakdown:
  • Total Gross Profit: $434.43 million
  • Total Operating Expenses: $181.59 million
How has Protagonist Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Protagonist Therapeutics' total revenue changed from $0.00 in 2015 to $434.43 million in 2024, a change of 43,443,300,000.0%.

How much debt does Protagonist Therapeutics have?

Protagonist Therapeutics' total liabilities were at $69.43 million at the end of 2024, a 226.4% increase from 2023, and a 1,222.7% increase since 2015.

How much cash does Protagonist Therapeutics have?

In the past 9 years, Protagonist Therapeutics' cash and equivalents has ranged from $4.06 million in 2015 to $186.73 million in 2023, and is currently $97.25 million as of their latest financial filing in 2024.

How has Protagonist Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Protagonist Therapeutics' book value per share changed from -108.85 in 2015 to 11.33 in 2024, a change of -110.4%.


Related Companies

This page (NASDAQ:PTGX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored